Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of radiation therapy and chemotherapy and kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of radiation therapy, chemotherapy and peripheral stem cell transplantation in treating patients with primitive neuroectodermal tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Carboplatin; Cyclophosphamide; Thiotepa; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven primitive neuroectodermal tumor (PNET) of one of the following types:

• Atypical teratoid/rhabdoid tumor

• Medulloblastoma

• Desmoplastic medulloblastoma

• Ependymoblastoma

• Medullomyoblastoma

• Spongioblastoma

• Spongioblastoma polare

• Primitive polar spongioblastoma

• Medulloepithelioma

• Neuroblastoma

• Pineoblastoma

• Posterior fossa PNET must be M1-3 or M0 with greater than 1.5 cm2 residual disease

• Non posterior fossa PNET and other types must be M0-3

• If M3, must show clear evidence of tumor on MRI

• No marrow involvement or other extraneural metastases

• No M4 disease

• No cord compression requiring emergency radiotherapy

PATIENT CHARACTERISTICS:

Age:

• 3 to 21

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Absolute neutrophil count at least 1,000/mm^3

• Platelet count at least 150,000/mm^3 (no platelet transfusions)

• Hemoglobin at least 10 g/dL (red blood cell transfusions allowed)

Hepatic:

• Bilirubin less than 1.5 times upper limit of normal (ULN)

• AST or ALT less than 2.5 times ULN

Renal:

• Creatinine clearance or glomerular filtration rate at least 70 mL/min

Cardiovascular:

• Shortening fraction greater than 27% by echocardiogram OR

• Ejection fraction greater than 47% by MUGA

Pulmonary:

• FEV_1/FVC greater than 60% except for children who:

• Are uncooperative

• Have no dyspnea at rest

• Have no exercise intolerance

• Have pulse oximetry greater than 94% on room air

Other:

• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• Not specified

Endocrine therapy:

• Steroids for increased intracranial pressure allowed

Radiotherapy:

• See Disease Characteristics

• No prior urgent radiotherapy

Surgery:

• Not specified

Other:

• No prior therapy for tumor